Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP)-RFA-CK-22-006, Clinical and Applied Research Strategies for the Prevention and Control of Fungal Diseases; Cancellation of Meeting, 11448 [2022-04259]
Download as PDF
<![CDATA[
11448
Federal Register / Vol. 87, No. 40 / Tuesday, March 1, 2022 / Notices
ESTIMATED ANNUALIZED BURDEN HOURS
Number of
responses per
respondent
Annual Reporting—Initial Population ......................
Annual Reporting—Subsequent Reporting .............
53
53
1
2
4
2
212
212
.................................................................................
....................
........................
....................
424
Form name
RPE-funded Health Departments (State, DC, and
Territories) and their Designated Delegates.
Total .................................................................
Jeffrey M. Zirger,
Lead, Information Collection Review Office,
Office of Scientific Integrity, Office of Science,
Centers for Disease Control and Prevention.
Prevention and the Agency for Toxic
Substances and Disease Registry.
Total
burden
(in hours)
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
BILLING CODE 4163–18–P
Centers for Disease Control and
Prevention
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Disease, Disability, and Injury
Prevention and Control Special
Emphasis Panel (SEP)—RFA–CK–22–
006, Clinical and Applied Research
Strategies for the Prevention and
Control of Fungal Diseases;
Cancellation of Meeting
Centers for Medicare & Medicaid
Services
McKesson, 7500 Security Boulevard,
Mail Stop: S3–02–01, Baltimore, MD
21244 or send via email to
MEDCACnomination@cms.hhs.gov.
FOR FURTHER INFORMATION CONTACT:
Ruth McKesson, MEDCAC Coordinator,
Centers for Medicare & Medicaid
Services, Center for Clinical Standards
and Quality, Coverage and Analysis
Group, S3–02–01, 7500 Security
Boulevard, Baltimore, MD 21244 or
contact Ms. McKesson by phone (410)
786–8611 or via email at
Ruth.McKesson@cms.hhs.gov.
SUPPLEMENTARY INFORMATION:
[CMS–3427–N]
I. Background
Medicare Program; Request for
Nominations for Members for the
Medicare Evidence Development &
Coverage Advisory Committee
The Secretary signed the initial
charter for the Medicare Coverage
Advisory Committee (MCAC) on
November 24, 1998. A notice in the
Federal Register (63 FR 68780)
announcing establishment of the MCAC
was published on December 14, 1998.
The MCAC name was updated to more
accurately reflect the purpose of the
committee and on January 26, 2007, the
Secretary published a notice in the
Federal Register (72 FR 3853),
announcing that the Committee’s name
changed to the Medicare Evidence
Development & Coverage Advisory
Committee (MEDCAC). The current
Secretary’s Charter for the MEDCAC is
available on the CMS website at: https://
www.cms.gov/Regulations-andGuidance/Guidance/FACA/Downloads/
medcaccharter.pdf or you may obtain a
copy of the charter by submitting a
request to the contact listed in the FOR
FURTHER INFORMATION section of this
notice.
The MEDCAC is governed by
provisions of the Federal Advisory
Committee Act, Public Law 92–463, as
amended (5 U.S.C. App. 2), which sets
forth standards for the formulation and
use of advisory committees, and is
authorized by section 222 of the Public
Health Service Act as amended (42
U.S.C. 217A).
We are requesting nominations for
candidates to serve on the MEDCAC.
Nominees are selected based upon their
individual qualifications and not solely
as representatives of professional
associations or societies. We wish to
[FR Doc. 2022–04192 Filed 2–28–22; 8:45 am]
BILLING CODE 4163–18–P
Kalwant Smagh,
Director, Strategic Business Initiatives Unit,
Office of the Chief Operating Officer, Centers
for Disease Control and Prevention.
[FR Doc. 2022–04259 Filed 2–28–22; 8:45 am]
Centers for Disease Control and
Prevention, Department of Health and
Human Services.
ACTION: Notice.
AGENCY:
Notice is
hereby given of a change in the meeting
of the Disease, Disability, and Injury
Prevention and Control Special
Emphasis Panel (SEP)—RFA–CK–22–
006, Clinical and Applied Research
Strategies for the Prevention and
Control of Fungal Diseases; April 14,
2022, 10:00 a.m.–5:00 p.m., EDT. The
teleconference was published in the
Federal Register on February 14, 2022,
Volume 87, Number 30, page 8251.
This meeting is being canceled in its
entirety.
FOR FURTHER INFORMATION CONTACT:
Gregory Anderson, M.S., M.P.H.,
Scientific Review Officer, CDC, National
Center for HIV, Viral Hepatitis, STD,
and TB Prevention, 1600 Clifton Road
NE, Mailstop US8–1, Atlanta, Georgia
30329, (404) 718–8833, ganderson@
cdc.gov.
The Director, Strategic Business
Initiatives Unit, Office of the Chief
Operating Officer, Centers for Disease
Control and Prevention, has been
delegated the authority to sign Federal
Register notices pertaining to
announcements of meetings and other
committee management activities, for
both the Centers for Disease Control and
SUPPLEMENTARY INFORMATION:
jspears on DSK121TN23PROD with NOTICES1
Average
burden per
response
(in hours)
Number of
respondents
Type of respondents
VerDate Sep<11>2014
19:01 Feb 28, 2022
Jkt 256001
Centers for Medicare &
Medicaid Services, HHS.
ACTION: Notice.
AGENCY:
This notice announces the
request for nominations for membership
on the Medicare Evidence Development
& Coverage Advisory Committee
(MEDCAC). Among other duties, the
MEDCAC provides advice and guidance
to the Secretary of the Department of
Health and Human Services (the
Secretary) and the Administrator of the
Centers for Medicare & Medicaid
Services (CMS) concerning the
adequacy of scientific evidence
available to CMS in making coverage
determinations under the Medicare
program. The MEDCAC’s fundamental
purpose is to support the principles of
an evidence-based determination
process for Medicare’s coverage
policies. MEDCAC panels provide
advice to CMS on the strength of the
evidence available for specific medical
treatments and technologies through a
public, participatory, and accountable
process.
DATES: Nominations must be received
by Monday, March 28, 2022.
ADDRESSES: You may mail nominations
for membership to the following
address: Centers for Medicare &
Medicaid Services, Center for Clinical
Standards and Quality, Attention: Ruth
SUMMARY:
PO 00000
Frm 00054
Fmt 4703
Sfmt 4703
E:\FR\FM\01MRN1.SGM
01MRN1
]]>Agencies
[Federal Register Volume 87, Number 40 (Tuesday, March 1, 2022)]
[Notices]
[Page 11448]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2022-04259]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
Disease, Disability, and Injury Prevention and Control Special
Emphasis Panel (SEP)--RFA-CK-22-006, Clinical and Applied Research
Strategies for the Prevention and Control of Fungal Diseases;
Cancellation of Meeting
AGENCY: Centers for Disease Control and Prevention, Department of
Health and Human Services.
ACTION: Notice.
-----------------------------------------------------------------------
SUPPLEMENTARY INFORMATION: Notice is hereby given of a change in the
meeting of the Disease, Disability, and Injury Prevention and Control
Special Emphasis Panel (SEP)--RFA-CK-22-006, Clinical and Applied
Research Strategies for the Prevention and Control of Fungal Diseases;
April 14, 2022, 10:00 a.m.-5:00 p.m., EDT. The teleconference was
published in the Federal Register on February 14, 2022, Volume 87,
Number 30, page 8251.
This meeting is being canceled in its entirety.
FOR FURTHER INFORMATION CONTACT: Gregory Anderson, M.S., M.P.H.,
Scientific Review Officer, CDC, National Center for HIV, Viral
Hepatitis, STD, and TB Prevention, 1600 Clifton Road NE, Mailstop US8-
1, Atlanta, Georgia 30329, (404) 718-8833, [email protected].
The Director, Strategic Business Initiatives Unit, Office of the
Chief Operating Officer, Centers for Disease Control and Prevention,
has been delegated the authority to sign Federal Register notices
pertaining to announcements of meetings and other committee management
activities, for both the Centers for Disease Control and Prevention and
the Agency for Toxic Substances and Disease Registry.
Kalwant Smagh,
Director, Strategic Business Initiatives Unit, Office of the Chief
Operating Officer, Centers for Disease Control and Prevention.
[FR Doc. 2022-04259 Filed 2-28-22; 8:45 am]
BILLING CODE 4163-18-P
